image: Dr. Zhavoronkov, a pioneer in generative biology and chemistry and an expert in longevity science, is a member of the WEF AI Governance Alliance
Credit: Insilico Medicine
Alex Zhavoronkov, PhD, founder and co-CEO of clinical stage artificial intelligence (AI)-driven drug discovery company Insilico Medicine will be attending the 54th Annual Meeting of the World Economic Forum (WEF) January 15-19 in Davos, Switzerland where the theme is “Rebuilding Trust.”
Zhavoronkov, a pioneer in generative biology and chemistry and an expert in longevity science, is a member of the WEF AI Governance Alliance and will contribute to the global conversation on AI development – including using AI to benefit global society and addressing how AI will interface with other technologies, including biotechnology.
He will discuss how AI is contributing to new breakthroughs in disease prevention and the science of reversing aging. On Jan. 16, he’ll participate in the Longevity Investors Lunch, and on January 19, 9:30am he will speak as part of a panel discussion at the WEF Open Forum called "Turning Back the Clock" at the Swiss Alpine School in Davos.
The annual meeting will convene representatives from 100 governments, all major international organizations, and 1,000 partner companies. It is designed to foster collaborations, bring recognition to global issues, and accelerate positive systemic change.
Insilico Medicine is a leading AI drug discovery company whose generative AI platform has driven the discovery and design of an internal pipeline of 30+ new molecules, a number of which are in clinical stages, for cancer, IBD, central nervous system diseases, and COVID-19 and related variants. The Company's lead drug, for the chronic, rare lung condition idiopathic pulmonary fibrosis, is the first AI-designed drug for an AI-discovered target to reach Phase II clinical trials with patients.
Ahead of his attendance at the meeting in Davos, Dr. Zhavoronkov wrote for the WEF’s Agenda blog on the waste inherent in the pharmaceutical industry and how AI can provide much needed efficiency.
“Generative AI has the ability to dramatically increase the chances of success of a therapeutic program by helping to pick the right disease target and generating a highly optimized molecule with desired properties, instead of searching for a needle in a haystack and identifying the list of indications where the target/mechanism-drug pair is likely to work,” Zhavoronkov writes. He also suggests that pharma can use AI to run parallel clinical trials for the same drug simultaneously in order to address multiple disease opportunities before the patent runs out, and to track the performance of management decision making.
“In the end,” he writes “accelerating the adoption of generative AI in the pharma industry is vital not only to the reduction of wasted resources, but to extending quality of life for everyone.”
About Insilico Medicine
Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com